Evidence map›Paper›PMID 29805566›Full record

ArticleOncology letters2018

miR-100 inhibits the migration and invasion of nasopharyngeal carcinoma by targeting IGF1R.

Xiaoyan Sun, Xiaoying Liu, Yanmei Wang, Shuqin Yang, Yao Chen, Tiejun Yuan

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiaoyan SunDepartment of Otorhinolaryngology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.
Xiaoying LiuDepartment of Otorhinolaryngology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.
Yanmei WangDepartment of Otorhinolaryngology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.
Shuqin YangDepartment of Otorhinolaryngology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.
Yao ChenDepartment of Otorhinolaryngology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.
Tiejun YuanDepartment of Otorhinolaryngology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.
Weifang People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is a cancer pattern that often develops in the epithelial cells of the nasopharynx. miR-100 is a miRNA that has been identified in a number of cancers. The aim of the present study was to investigate whether miR-100 can affect cell migration and proliferation of NPC by targeting insulin-like growth factor 1 receptor (IGF1R). Western blot analysis was used to determine the protein levels of genes. The reverse transcription-quantitative PCR (RT-qPCR) was used to detect the expression level of miR-100 and IGF1R. Transwell assay was used to detect the migration and invasion of cell lines. The luciferase reporter assay was employed to confirm the target gene of miR-100. miR-100 expression was highly reduced in NPC tissues compared with non-cancerous tissues. Overexpression of miR-100 significantly inhibited the migration and invasion of NPC cell lines

Indexed as

IGF1RinvasionmigrationmiR-100

Identifiers

PMID29805566
PMCPMC5950178
OpenAlexW2796111507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.